199 related articles for article (PubMed ID: 7842405)
1. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma.
MacFarlane MP; Yang JC; Guleria AS; White RL; Seipp CA; Einhorn JH; White DE; Rosenberg SA
Cancer; 1995 Feb; 75(4):1030-7. PubMed ID: 7842405
[TBL] [Abstract][Full Text] [Related]
2. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.
Guleria AS; Yang JC; Topalian SL; Weber JS; Parkinson DR; MacFarlane MP; White RL; Steinberg SM; White DE; Einhorn JH
J Clin Oncol; 1994 Dec; 12(12):2714-22. PubMed ID: 7989949
[TBL] [Abstract][Full Text] [Related]
3. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
[TBL] [Abstract][Full Text] [Related]
4. Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer.
Marroquin CE; White DE; Steinberg SM; Rosenberg SA; Schwartzentruber DJ
J Immunother; 2000; 23(3):387-92. PubMed ID: 10838668
[TBL] [Abstract][Full Text] [Related]
5. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
Lindsey KR; Rosenberg SA; Sherry RM
J Clin Oncol; 2000 May; 18(9):1954-9. PubMed ID: 10784637
[TBL] [Abstract][Full Text] [Related]
6. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; AramendÃa JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.
Bulgarelli J; Piccinini C; Petracci E; Pancisi E; Granato AM; de Rosa F; Guidoboni M; Petrini M; Ancarani V; Foschi G; Romeo A; Tontini L; De Giorgi U; Lolli C; Gentili G; Valmorri L; Rossi A; Ferroni F; Casadei C; Cortesi P; Crudi L; Ridolfi L
Front Immunol; 2021; 12():778459. PubMed ID: 34777395
[TBL] [Abstract][Full Text] [Related]
8. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
9. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
11. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
[TBL] [Abstract][Full Text] [Related]
12. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
Du Bois JS; Trehu EG; Mier JW; Shapiro L; Epstein M; Klempner M; Dinarello C; Kappler K; Ronayne L; Rand W; Atkins MB
J Clin Oncol; 1997 Mar; 15(3):1052-62. PubMed ID: 9060545
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
14. Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.
Sosman JA; Kohler PC; Hank J; Moore KH; Bechhofer R; Storer B; Sondel PM
J Natl Cancer Inst; 1988 Mar; 80(1):60-3. PubMed ID: 3257526
[TBL] [Abstract][Full Text] [Related]
15. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma.
White RL; Schwartzentruber DJ; Guleria A; MacFarlane MP; White DE; Tucker E; Rosenberg SA
Cancer; 1994 Dec; 74(12):3212-22. PubMed ID: 7982185
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.
Yang JC; Topalian SL; Parkinson D; Schwartzentruber DJ; Weber JS; Ettinghausen SE; White DE; Steinberg SM; Cole DJ; Kim HI
J Clin Oncol; 1994 Aug; 12(8):1572-6. PubMed ID: 8040669
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
Galanis E; Hersh EM; Stopeck AT; Gonzalez R; Burch P; Spier C; Akporiaye ET; Rinehart JJ; Edmonson J; Sobol RE; Forscher C; Sondak VK; Lewis BD; Unger EC; O'Driscoll M; Selk L; Rubin J
J Clin Oncol; 1999 Oct; 17(10):3313-23. PubMed ID: 10506635
[TBL] [Abstract][Full Text] [Related]
18. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.
Rosenberg SA; Yang JC; White DE; Steinberg SM
Ann Surg; 1998 Sep; 228(3):307-19. PubMed ID: 9742914
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of escalating doses of interleukin-1 beta in combination with a fixed dose of interleukin-2.
Triozzi PL; Kim JA; Martin EW; Young DC; Benzies T; Villasmil PM
J Clin Oncol; 1995 Feb; 13(2):482-9. PubMed ID: 7844609
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
